retatrutide triple agonist glp-1 gip glucagon phase 2 results Efficacy and safety of retatrutide, a GIP, GLP-1, and receptor agonist, in people with type diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Lilly's triple agonist, retatrutide, successful

A recent analysis of 48 studies found that after one year of getting off GLP-1s, patients regained 60% of their original weight loss

In this review, we summarize the role of oxidative stress in the pathophysiology of IBD, its diagnostic targets, and the potential application of antioxidant therapies to manage and treat IBD

Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis

Glutathione has been shown to protect the nervous system against various forms of damage as well, and is being widely researched for the same

Revision surgery is a viable option for many patients